Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab IV re-induction versus continued subcutaneous maintenance in Crohn's disease with secondary loss of response
NL-OMON52420Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response at Week 16. Started Aug 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON52420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52420.